SaudiVax

GMP-Certified Biomanufacturing Hub

Engineering the Future of Sovereign Healthcare Security

Pioneering sovereign biomanufacturing to transform healthcare, strengthen pandemic resilience, and position Saudi Arabia at the forefront of global biotechnology innovation.

Explore Our Mission View Pipeline

SFDA Compliant• FDA Aligned• EMA Referenced• Vision 2030 Initiative• BSL-3 Infrastructure• Ministry of Investment• KAIMRC Partner•

Vision 2030 Alignment

Driving National Transformation

Our strategic milestones are aligned with Saudi Arabia's Vision 2030 objectives for healthcare self-sufficiency, economic diversification, and high-value job creation.

Biotech GDP Target (2040)

$0B

Contribution to Biotech GDP Target

Vaccine Localization

End-to-End Vaccine Localization

Employment Pipeline

High-Value Job Creation Pipeline

Our Vision

Transforming Healthcare Through Saudi Innovation

We're building the Middle East's most advanced biomanufacturing ecosystem, combining cutting-edge technology with Saudi Arabia's strategic vision to create a self-sufficient pharmaceutical future.

Vaccine Independence

Achieving 70% vaccine self-sufficiency by 2030 through localized production.

Innovation Leadership

Establishing Saudi Arabia as the MENA region's biotech innovation hub.

Clinical Pipeline

Therapeutic Development Pipeline

Active programs spanning oncology, infectious disease, and rare disease across clinical phases.

Active

Enrolling

Planning

Candidate

Target

Phase

Status

Progress

Discovery

Preclinical

Phase I

Phase II

Phase III

Approval

Our Science

Molecular Innovation Platform

From computational discovery to GMP manufacturing, our integrated platform accelerates the journey from molecule to medicine.

Discovery Phase

Proprietary mRNA Platform

Our computational biology pipeline leverages AI-driven antigen selection to identify optimal mRNA sequences. Modified nucleosides ensure enhanced translational efficiency and reduced innate immunogenicity.

4,200+

Candidates screened

72hrs

Design-to-construct

Formulation Phase

Lipid Nanoparticle Delivery

Ionizable lipid nanoparticles encapsulate mRNA cargo with >95% encapsulation efficiency. Proprietary PEGylation chemistry ensures optimal biodistribution and cellular uptake in target antigen-presenting cells.

95.2%

Encapsulation rate

80nm

Mean particle size

Scale-Up Phase

GMP Manufacturing at Scale

Continuous-flow microfluidic mixing enables seamless transition from bench to commercial scale. Single-use bioreactor systems ensure batch-to-batch consistency while minimizing cross-contamination risk.

200K L

Bioreactor capacity

500M

Annual doses

Manufacturing Infrastructure

Sovereign Manufacturing Capacity

Capital-intensive, GMP-certified biomanufacturing infrastructure engineered for national self-sufficiency.

200,000L

Bioreactor Capacity

2,000L single-use systems with mammalian and microbial platforms

500M

Annual Dose Output

Fill-finish and lyophilization across multiple vaccine formats

ISO 5

Cleanroom Classification

Class 100 equivalent with continuous environmental monitoring

BSL-3

Biosafety Level

Full containment capability for pathogen handling and viral vector production

GMP Certifications

SFDA GMP Compliance
FDA cGMP Aligned
EMA Annex 1 Referenced
WHO Prequalification Pathway

Technology Platforms

mRNA / Modified Nucleoside
Viral Vector (AAV, Adenovirus)
Recombinant Protein Expression
Monoclonal Antibody (CHO)

Quality Systems

Real-time PAT Analytics
HPLC / Mass Spectrometry
Electronic Batch Records
Cold Chain (-70°C to +8°C)

Strategic Partnering

The MENA Biomanufacturing Advantage

Saudi Arabia's strategic geographic position at the crossroads of Europe, Africa, and Asia, combined with sovereign capital commitment and regulatory fast-tracking, creates an unparalleled biomanufacturing investment thesis.

Direct market access to 450M+ population across the GCC and MENA region

Sovereign-backed funding with Vision 2030 capital allocation

Accelerated SFDA regulatory pathway for domestic manufacturers

Technology transfer agreements with global pharma leaders

Explore Partnership

$34.6B

National Biotech GDP Target

450M+

Addressable Population

3 hrs

Flight to 40% of Global Pop.

Corporate Income Tax (SEZ)